-
Injured Australian swim star O'Callaghan pulls out of PanPacs
-
Veteran Wallabies playmaker Quade Cooper eyes World Cup comeback
-
California lifeguards wiped out from extreme weather
-
FIFA scraps private investment plan after backlash
-
FIFA scraps private investment plan after backlash: Infantino
-
US plans steep water cuts for southwest amid Colorado River crisis
-
South Africa's WAFCON hopes hang in the balance after dramatic draw
-
Nakashima ousts top seed de Minaur, Osaka advances at Washington
-
Hunter Bell cruises to Commonwealth gold, Pathirage stuns javelin stars
-
Nakashima ousts top seed de Minaur and Osaka advances at Washington
-
Amazon surges as US stocks shrug off bond yield worries
-
Nakashima ousts defending champion de Minaur to reach Washington semis
-
Google rolls back new satellite image AI tool after backlash
-
Magaia salvages last-gasp WAFCON draw for South Africa
-
Ryu leads in bid for third straight major at women's British Open
-
Forever chemicals and pesticides under Trump: what to know
-
Fire-hit France region 'coming up for air' as main blaze calms
-
US announces steep water cuts for three states amid Colorado River crisis
-
Wembanyama to get signature shoe in Nike contract extension: reports
-
EU grapples with migrant crisis in Spain's N. Africa enclave
-
Oil giants report blowout profits on war, warn high gas prices could persist
-
Hungary to shut nuclear plant as heatwave hits central Europe
-
Google launches new satellite image AI tool, alarming researchers
-
Strengthening El Nino 'adding fuel to a planet already on fire': UN chief
-
Eddie Howe resigns as Newcastle boss to 'recharge'
-
Tech-fuelled rally fizzles as oil prices rise
-
High winds hamper firefighting efforts in western Turkey
-
Chelsea's Mudryk cleared to play after doping ban appeal
-
Howe resigns as Newcastle boss
-
A side of oysters for France's flat-out firefighters
-
Full-scale tour will benefit All Blacks, says coach Rennie
-
England cricket chief Key refuses to rule out Stokes return
-
US Fed dissenters call for rate hikes over sustained inflation
-
New blazes in Greece as strong winds hamper firefighting
-
Trump and far-right seize on Spanish migration crisis
-
Springboks star Feinberg-Mngomezulu back for Argentina Test
-
Hamas agrees to disarm under Trump plan
-
Shops closed, businesses quiet as Spain's Ceuta faces migrant surge
-
French, Italian winegrowers face earliest ever harvest
-
Chelsea fined £10mn, handed suspended transfer ban for breaching agent rules
-
Alarm over climate-linked low level of German waterways
-
Residents defend Spain’s ancient 'El Abuelo' tree from flames
-
UK court rejects challenge against new Chinese embassy in London
-
Forever chemicals and pesticides: what to know
-
New York sues online prediction markets giant Kalshi
-
Spaniard Santi Denia takes over as Czech Republic coach
-
Commerzbank agrees to talks with UniCredit after two-year standoff
-
EU races to contain new migrant crisis as thousands cross into Spain's N. Africa enclave
-
A rumour, a rush: chaos at Morocco border with Spain's Ceuta
-
Profits surge at US oil giant amid Iran war supply shock
Trump administration does about face on autism treatment
The Trump administration did an about-face Tuesday on an autism treatment it had promoted with great fanfare.
It had said back in September it would approve use of a drug called leucovorin -- synthetic vitamin B9 -- to treat the disorder.
But on Tuesday the Food and Drug Administration backed off, citing insufficient evidence that it works for the condition.
The initial announcement came from Health Secretary Robert F. Kennedy Jr, who for decades has spread debunked claims that vaccines cause autism.
Kennedy touted leucovorin, usually used to alleviate chemotherapy side effects, as an "exciting therapy" that could help children with autism, a disorder whose symptoms vary widely across a spectrum.
"This gives hope to the many parents with autistic children that it may be possible to improve their lives," President Donald Trump said in September at a press conference.
At the event he gave sweeping, unsubstantiated advice on autism, such as insisting that pregnant women should "tough it out" and avoid Tylenol over an unproven link to autism -- statements slammed by scientists.
Studies on a small number of patients have suggested that taking leucovorin can help ease some communication or personal-relations problems linked to autism, but experts say this issue needs more study.
On Tuesday the FDA said it was in fact approving use of leucovorin for a rare condition called cerebral folate deficiency but not for autism.
The Trump administration's touting of it for autism ran the risk of raising false hopes, dozens of autism specialists said at the time in a joint letter.
"We don't have sufficient data to say that we could establish efficacy for autism more broadly," an FDA official told NBC News.
"It'll be up to patients to talk with their physicians to see if that might be right for them," said the official, whose name was not given.
C.Stoecklin--VB